Recon: AstraZeneca buys rare disease drugmaker Caelum; FDA considering half-dose Moderna booster
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy